Cassava Sciences Rebrands as Filana Therapeutics, Sharpening Focus on TSC-Related Epilepsy
Market Chameleon (Tue, 10-Mar 7:19 AM ET)
Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.
Globe Newswire (Tue, 10-Mar 8:00 AM ET)
Cassava Announces Closure of U.S. Department of Justice Investigation
Globe Newswire (Thu, 19-Feb 8:00 AM ET)
Globe Newswire (Tue, 13-Jan 8:00 AM ET)
PRNewswire (Wed, 24-Dec 11:51 AM ET)
Cassava Announces Agreement to Settle Securities Class Action Litigation
Globe Newswire (Tue, 23-Dec 8:00 AM ET)
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
Cassava Sciences trades on the NASDAQ stock market under the symbol SAVA.
As of March 20, 2026, SAVA stock price was flat at $2.38 with million shares trading.
SAVA has a beta of 1.76, meaning it tends to be more sensitive to market movements. SAVA has a correlation of 0.10 to the broad based SPY ETF.
SAVA has a market cap of $114.97 million. This is considered a Micro Cap stock.
In the last 3 years, SAVA traded as high as $42.20 and as low as $1.15.
SAVA has underperformed the market in the last year with a return of -13.8%, while SPY returned +16.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in SAVA shares. However, SAVA has outperformed the market in the last 3 month and 2 week periods, returning +9.4% and +17.2%, while SPY returned -4.4% and -3.3%, respectively. This indicates SAVA has been having a stronger performance recently.
SAVA support price is $2.27 and resistance is $2.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SAVA shares will trade within this expected range on the day.
